Subject Expert Committee recommends Covaxin for 2-18 year-olds

The Subject Expert Committee on COVID-19 has recommended Bharat Biotech’s Covaxin for 2-18 year-olds.

Bharat Biotech’s COVID-19 vaccine, Covaxin, has been recommended for emergency use approval to the DCGI by the expert panel.

If approved by the drugs regulator, Covaxin will become the second vaccine, after Zydus Cadila’s ZyCoV-D, to be approved for inoculating children in the country.